10-Q · May 14, 2026
AEON Biopharma reported no revenue in its Q4 2026 quarterly filing, with a notable EPS decline to -3.72 from -0.6 in the previous quarter. Operating expenses increased primarily due to rising SG&A and R&D costs. The…
Earnings analysis · 10-Q
AEON earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
AEON’s Q2 diluted loss improved to $0.02 per share from $0.60 year over year and $0.29 in Q1 2026, but the filing does not provide revenue, margin, segment, or free-cash-flow data. Approximately $13.6 million of July…
Read full summary
AEON’s Q2 diluted loss improved to $0.02 per share from $0.60 year over year and $0.29 in Q1 2026, but the filing does not provide revenue, margin, segment, or free-cash-flow data. Approximately $13.6 million of July financing proceeds extends the expected operating runway into Q1 2027, while the $15.361 million stockholders’ deficit and continuing losses remain significant concerns. The newly issued pre-funded and milestone warrants add material dilution risk, although the Aegis lawsuit was dismissed with prejudice in April 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.02
What stood out
-
Quarterly loss narrowed materially
Second-quarter diluted loss narrowed to $0.02 per share from a $0.60 loss in the prior-year quarter and a $0.29 loss in Q1 2026.
-
Financing extends operating runway
The July 2026 financing generated approximately $13.6 million of net proceeds, with liquidity expected to fund operations into Q1 2027.
-
Disclosure controls remained effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
-
Capital-markets lawsuit dismissed
AEON’s motion to dismiss Aegis Capital’s lawsuit was granted with prejudice in April 2026; Aegis had claimed $1.59 million in damages and did not appeal.
What to watch
-
New financing creates dilution risk
The July 2026 financing included common shares, pre-funded warrants, and two-year and five-year milestone warrants. Exercise of these instruments could materially dilute existing holders and create trading pressure.
-
Limited liquidity runway
The company has approximately $13.6 million of July financing proceeds expected to fund operations only into Q1 2027, indicating that additional capital may be needed thereafter.
-
Deficit and continuing-loss risk
AEON reported a $15.361 million stockholders’ deficit and continues to incur operating losses, increasing dependence on future financing and successful product development.
Management's outlook
No numeric revenue or EPS guidance was provided. Management indicated that approximately $13.6 million of July 2026 financing proceeds are expected to fund operations into Q1 2027.
Earlier filings 4
10-K · March 30, 2026
AEON’s 10-K frames a focused strategy to commercialize ABP-450 as a Section 351(k) biosimilar to Botox® for therapeutic indications, highlighting strong early analytical comparability data (100% amino acid identity;…
10-Q · November 14, 2025
AEON reported a narrower net loss in Q3 2025 of $4.538 million (basic EPS -$0.39) versus a loss of $6.171 million (EPS -$11.24) in Q3 2024, driven by lower operating expenses and non‑cash fair value movements. Cash…
10-Q · May 14, 2025
AEON reported a non-cash net income of $9,095,000 for Q1 2025 (vs. a net loss of $118,018,000 in Q1 2024) driven by fair‑value movements in warrants and related instruments. Operating loss narrowed to $(462,000) from…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.